Browse PITX2

Summary
SymbolPITX2
Namepaired-like homeodomain 2
Aliases IGDS; Brx1; Otlx2; IRID2; IHG2; RIEG; RIEG1; RGS; paired-like homeodomain transcription factor 2; IDG2; IGDS ......
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF00046 Homeobox domain
PF03826 OAR domain
Function

Controls cell proliferation in a tissue-specific manner and is involved in morphogenesis. During embryonic development, exerts a role in the expansion of muscle progenitors. May play a role in the proper localization of asymmetric organs such as the heart and stomach. Isoform PTX2C is involved in left-right asymmetry the developing embryo (By similarity).

> Gene Ontology
 
Biological Process GO:0000768 syncytium formation by plasma membrane fusion
GO:0001501 skeletal system development
GO:0001525 angiogenesis
GO:0001569 patterning of blood vessels
GO:0001570 vasculogenesis
GO:0001654 eye development
GO:0001667 ameboidal-type cell migration
GO:0001701 in utero embryonic development
GO:0001755 neural crest cell migration
GO:0001763 morphogenesis of a branching structure
GO:0001764 neuron migration
GO:0002074 extraocular skeletal muscle development
GO:0003002 regionalization
GO:0003007 heart morphogenesis
GO:0003151 outflow tract morphogenesis
GO:0003170 heart valve development
GO:0003171 atrioventricular valve development
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0003209 cardiac atrium morphogenesis
GO:0003228 atrial cardiac muscle tissue development
GO:0003230 cardiac atrium development
GO:0003231 cardiac ventricle development
GO:0003253 cardiac neural crest cell migration involved in outflow tract morphogenesis
GO:0003279 cardiac septum development
GO:0003281 ventricular septum development
GO:0003350 pulmonary myocardium development
GO:0006949 syncytium formation
GO:0007368 determination of left/right symmetry
GO:0007389 pattern specification process
GO:0007423 sensory organ development
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0007520 myoblast fusion
GO:0007548 sex differentiation
GO:0007584 response to nutrient
GO:0008406 gonad development
GO:0008544 epidermis development
GO:0008584 male gonad development
GO:0008585 female gonad development
GO:0009798 axis specification
GO:0009799 specification of symmetry
GO:0009855 determination of bilateral symmetry
GO:0009913 epidermal cell differentiation
GO:0009991 response to extracellular stimulus
GO:0014031 mesenchymal cell development
GO:0014032 neural crest cell development
GO:0014033 neural crest cell differentiation
GO:0014706 striated muscle tissue development
GO:0014902 myotube differentiation
GO:0016055 Wnt signaling pathway
GO:0021536 diencephalon development
GO:0021539 subthalamus development
GO:0021761 limbic system development
GO:0021763 subthalamic nucleus development
GO:0021854 hypothalamus development
GO:0021855 hypothalamus cell migration
GO:0021983 pituitary gland development
GO:0021984 adenohypophysis development
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030326 embryonic limb morphogenesis
GO:0030900 forebrain development
GO:0031076 embryonic camera-type eye development
GO:0031667 response to nutrient levels
GO:0033189 response to vitamin A
GO:0033273 response to vitamin
GO:0035051 cardiocyte differentiation
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0035116 embryonic hindlimb morphogenesis
GO:0035137 hindlimb morphogenesis
GO:0035239 tube morphogenesis
GO:0035270 endocrine system development
GO:0035315 hair cell differentiation
GO:0035886 vascular smooth muscle cell differentiation
GO:0035993 deltoid tuberosity development
GO:0042475 odontogenesis of dentin-containing tooth
GO:0042476 odontogenesis
GO:0042692 muscle cell differentiation
GO:0043010 camera-type eye development
GO:0043388 positive regulation of DNA binding
GO:0045137 development of primary sexual characteristics
GO:0046545 development of primary female sexual characteristics
GO:0046546 development of primary male sexual characteristics
GO:0046660 female sex differentiation
GO:0046661 male sex differentiation
GO:0048514 blood vessel morphogenesis
GO:0048536 spleen development
GO:0048546 digestive tract morphogenesis
GO:0048557 embryonic digestive tract morphogenesis
GO:0048562 embryonic organ morphogenesis
GO:0048565 digestive tract development
GO:0048566 embryonic digestive tract development
GO:0048568 embryonic organ development
GO:0048592 eye morphogenesis
GO:0048593 camera-type eye morphogenesis
GO:0048608 reproductive structure development
GO:0048644 muscle organ morphogenesis
GO:0048732 gland development
GO:0048736 appendage development
GO:0048738 cardiac muscle tissue development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048762 mesenchymal cell differentiation
GO:0048845 venous blood vessel morphogenesis
GO:0048857 neural nucleus development
GO:0048863 stem cell differentiation
GO:0048864 stem cell development
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0051101 regulation of DNA binding
GO:0051145 smooth muscle cell differentiation
GO:0051146 striated muscle cell differentiation
GO:0051450 myoblast proliferation
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
GO:0055006 cardiac cell development
GO:0055007 cardiac muscle cell differentiation
GO:0055008 cardiac muscle tissue morphogenesis
GO:0055009 atrial cardiac muscle tissue morphogenesis
GO:0055012 ventricular cardiac muscle cell differentiation
GO:0055013 cardiac muscle cell development
GO:0055015 ventricular cardiac muscle cell development
GO:0055123 digestive system development
GO:0060126 somatotropin secreting cell differentiation
GO:0060127 prolactin secreting cell differentiation
GO:0060173 limb development
GO:0060348 bone development
GO:0060411 cardiac septum morphogenesis
GO:0060412 ventricular septum morphogenesis
GO:0060415 muscle tissue morphogenesis
GO:0060425 lung morphogenesis
GO:0060459 left lung development
GO:0060460 left lung morphogenesis
GO:0060485 mesenchyme development
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0060541 respiratory system development
GO:0060562 epithelial tube morphogenesis
GO:0060577 pulmonary vein morphogenesis
GO:0060578 superior vena cava morphogenesis
GO:0060841 venous blood vessel development
GO:0060972 left/right pattern formation
GO:0060973 cell migration involved in heart development
GO:0061031 endodermal digestive tract morphogenesis
GO:0061072 iris morphogenesis
GO:0061138 morphogenesis of a branching epithelium
GO:0061307 cardiac neural crest cell differentiation involved in heart development
GO:0061308 cardiac neural crest cell development involved in heart development
GO:0061309 cardiac neural crest cell development involved in outflow tract morphogenesis
GO:0061323 cell proliferation involved in heart morphogenesis
GO:0061325 cell proliferation involved in outflow tract morphogenesis
GO:0061458 reproductive system development
GO:0070986 left/right axis specification
GO:0090596 sensory organ morphogenesis
GO:0198738 cell-cell signaling by wnt
GO:2000288 positive regulation of myoblast proliferation
GO:2000291 regulation of myoblast proliferation
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001085 RNA polymerase II transcription factor binding
GO:0001102 RNA polymerase II activating transcription factor binding
GO:0001104 RNA polymerase II transcription cofactor activity
GO:0001105 RNA polymerase II transcription coactivator activity
GO:0001159 core promoter proximal region DNA binding
GO:0001190 transcriptional activator activity, RNA polymerase II transcription factor binding
GO:0001191 transcriptional repressor activity, RNA polymerase II transcription factor binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0003713 transcription coactivator activity
GO:0008134 transcription factor binding
GO:0031490 chromatin DNA binding
GO:0033613 activating transcription factor binding
GO:0043566 structure-specific DNA binding
GO:0098811 transcriptional repressor activity, RNA polymerase II activating transcription factor binding
Cellular Component GO:0005667 transcription factor complex
> KEGG and Reactome Pathway
 
KEGG hsa04350 TGF-beta signaling pathway
Reactome R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-8866906: TFAP2 (AP-2) family regulates transcription of other transcription factors
R-HSA-8864260: Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors
Summary
SymbolPITX2
Namepaired-like homeodomain 2
Aliases IGDS; Brx1; Otlx2; IRID2; IHG2; RIEG; RIEG1; RGS; paired-like homeodomain transcription factor 2; IDG2; IGDS ......
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PITX2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPITX2
Namepaired-like homeodomain 2
Aliases IGDS; Brx1; Otlx2; IRID2; IHG2; RIEG; RIEG1; RGS; paired-like homeodomain transcription factor 2; IDG2; IGDS ......
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PITX2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.56; FDR: 0.04180 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPITX2
Namepaired-like homeodomain 2
Aliases IGDS; Brx1; Otlx2; IRID2; IHG2; RIEG; RIEG1; RGS; paired-like homeodomain transcription factor 2; IDG2; IGDS ......
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PITX2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.050.906
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6210.369
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5280.417
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7970.115
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.9640.499
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5820.723
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7170.461
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.5990.244
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.230.875
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2240.807
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.3280.277
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5260.127
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PITX2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPITX2
Namepaired-like homeodomain 2
Aliases IGDS; Brx1; Otlx2; IRID2; IHG2; RIEG; RIEG1; RGS; paired-like homeodomain transcription factor 2; IDG2; IGDS ......
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PITX2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPITX2
Namepaired-like homeodomain 2
Aliases IGDS; Brx1; Otlx2; IRID2; IHG2; RIEG; RIEG1; RGS; paired-like homeodomain transcription factor 2; IDG2; IGDS ......
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PITX2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PITX2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPITX2
Namepaired-like homeodomain 2
Aliases IGDS; Brx1; Otlx2; IRID2; IHG2; RIEG; RIEG1; RGS; paired-like homeodomain transcription factor 2; IDG2; IGDS ......
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PITX2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPITX2
Namepaired-like homeodomain 2
Aliases IGDS; Brx1; Otlx2; IRID2; IHG2; RIEG; RIEG1; RGS; paired-like homeodomain transcription factor 2; IDG2; IGDS ......
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PITX2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPITX2
Namepaired-like homeodomain 2
Aliases IGDS; Brx1; Otlx2; IRID2; IHG2; RIEG; RIEG1; RGS; paired-like homeodomain transcription factor 2; IDG2; IGDS ......
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PITX2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPITX2
Namepaired-like homeodomain 2
Aliases IGDS; Brx1; Otlx2; IRID2; IHG2; RIEG; RIEG1; RGS; paired-like homeodomain transcription factor 2; IDG2; IGDS ......
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PITX2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.